| Texto completo | |
| Autor(es): |
Cerda, Alvaro
[1]
;
Genvigir, Fabiana Dalla Vecchia
[1]
;
Rodrigues, Alice Cristina
[1]
;
Vieira Willrich, Maria Alice
[1]
;
Dorea, Egidio Lima
[2]
;
Silveira Bernik, Marcia Martins
[2]
;
Arazi, Simone Sorkin
[1]
;
de Oliveira, Raquel
[1]
;
Hirata, Mario Hiroyuki
[1]
;
Crespo Hirata, Rosario Dominguez
[1]
Número total de Autores: 10
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, BR-05508900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Univ Hosp, BR-05508900 Sao Paulo - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo Científico |
| Fonte: | JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS; v. 18, n. 8, p. 640-651, 2011. |
| Citações Web of Science: | 9 |
| Resumo | |
Aim: This study evaluated the influence of polymorphisms and cholesterol-lowering treatments on SCARB1 mRNA expression in peripheral blood mononuclear cells and in HepG2 and Caco-2 cells. Methods: Blood samples were drawn from normolipidemic (NL, n = 166) and hypercholesterolemic (HC, n = 123) individuals to extract DNA and total RNA and to analyze the lipid profile. After a 4-week washout period, 98 HC individuals were treated with atorvastatin (10 mg/day/4 weeks) whereas 25 were treated with ezetimibe (10 mg/day/4 weeks), followed by simvastatin (10 mg/day/8 weeks) and simvastatin plus ezetimibe (10 mg each/day/4 weeks). HepG2 and Caco-2 cells were treated with atorvastatin, simvastatin and ezetimibe at various concentrations for 12 and 24 h and collected for RNA extraction. SCARB1 mRNA expression was measured by TaqMan (R) assay and SCARB1 c.4G > A, c.726 + 54C > T and c.1080C > T polymorphisms were detected by PCR-RFLP. Results: High LDL cholesterol (> 160 mg/dL) values were associated with low baseline SCARB1 mRNA expression in PBMC. Allele T carriers for SCARB1 c.726 + 54C > T had lower basal SCARB1 transcription in PBMC (p < 0.05). Simvastatin, atorvastatin and ezetimibe treatments did not modify the SCARB1 mRNA level in PBMC from HC patients. Similarly, these cholesterol-lowering drugs did not modulate the SCARB1 expression in HepG2 and Caco-2 cells in spite of the concentration and time of exposure (p > 0.05). Conclusion: LDL cholesterol levels and SCARB1 c.726 + 54C > T are associated with low mRNA expression in mononuclear cells. Cholesterol-lowering drugs do not modulate SCARB1 expression in PBMC from HC subjects or in HepG2 and Caco-2 cells. (AU) | |
| Processo FAPESP: | 09/15125-8 - Influência de inibidores de síntese e absorção de colesterol na expressão de proteínas do transporte reverso do colesterol em células HepG2 e CACO-2 |
| Beneficiário: | Rosario Dominguez Crespo Hirata |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |